anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain a dermal agent for external use, capable of improving the skin state of an atopic dermatitis patient by using squalene or/and squalene in combination with glycerin and/or erythritol. CONSTITUTION:This dermal agent for external use is prepared by using (a) squalane or/and squalene in combination with (b) glycerin and/or erythritol. The amount of the component (a) is preferably equal to or more than that of the component (b) and the amount of the component (b) is especially preferably &gt;=8wt.%. The other hand, the content of the component (a) is preferably &gt;=50wt.% based on the oil components. Hyaluronic acid or its salt is recommendably further added to this composition in an amount of &gt;=0.001wt.%. This dermal agent for external use can improve roughness of the skin and prevent the skin from drying. This dermal agent is effective especially for therapy of xeroderma and ichthyosis which occur frequently in an atopic dermatitis patient. The effect for improving roughness of the skin or preventing the skin from drying can be improved by adding hyaluronic acid or its salt to the dermal agent of external use.
NEW MATERIAL:The compound of formula I [R&lt;1&gt; is H or 1-5C alkyl; R&lt;2&gt;-R&lt;4&gt; are H, 1-5C alkoxy or OH; two of R&lt;2&gt;-R&lt;4&gt; may together form the group of formula IV or formula V; m is 0-4; n is 1-4; dotted line is single bond or double bond] or its salt. EXAMPLE:The compound of formula VI. USE:A medicine. A cardiotonic agent. It is administered orally or parenterally at a dose of 0.1-10mg/kg body weight daily in the case of oral administration. PREPARATION:The compound of formula I can be produced e.g. by reacting a carboxylic acid of formula II with an alkyl halocarboxylate such as ethyl chloroformate in a mixed solvent consisting of N,N-dimethylformamide and tetrahydrofuran, etc., at -20-+100 deg.C for 5-10hr in the presence of a basic compound such as triethylamine and reacting the resultant mixed acid anhydride with an amine of formula III at -20-+100 deg.C for 5min-10hr.
Technologies are generally described for normalized standard deviation transition based dosimetry monitoring for laser treatment. In some examples, a response signal may be generated based on a physical response to a laser pulse detected through acoustic or optical means. Each response signal may be a time series of data with a number of points. Standard deviation may be determined for each response signal and normalized using a mean or comparable normalization factor. Thus, a robust distribution may be computed from the response to each laser pulse. A change in the normalized standard deviation from each single pulse&#39;s time domain response data may be used to determine how many laser pulses remain before completion of the treatment (similar to event onset response). Thus, laser treatment may be continued based on an estimation of remaining pulses for completion or ceased if completion is reached.
PURPOSE:To obtain the titled compound having a novel structure and useful as an antitumor agent or an intermediate thereof in high yield, by reacting a tetrachloroplatinate with a hydriodate and a specific diamine by a specific method. CONSTITUTION:Into an aqueous solution of a tetrachloroplatinate expressed by the formula M2PtCl4 (M represents atom capable of forming monovalent cation), are added a hydriodate expressed by the formula M&#39;I (M&#39; is same as M) and an aqueous solution of a diamine expressed by formula I (R1-R8 represent H, lower alkyl or OH) and mixed at a low temperature of &lt;=15 deg.C to carry out reaction of these compounds in an aqueous solution of low concentration and afford the aimed compound expressed by formula II. As for the compound expressed by formula I, for example, 1,4-butanediamine, etc., are used. A concentration of the tetrachloroplatinate in the reaction liquid is preferably controlled in 1X10&lt;-2&gt;-5X10&lt;-2&gt;mol./l, and 4-8mol. iodate and 0.9-1.2mol. diamine are preferably used respectively based on 1mol. tetrachloroplatinate.
PROBLEM TO BE SOLVED: To provide a dermal external agent having a high skin-beutifying activity, stable and not having problems in its safety such as skin-irritating property and skin sensitivity. SOLUTION: This dermal external agent is obtained by blending the following components A to C simultaneously. Component A: An extract of plants belonging to the Polygonum L. of 1 kind or &gt;=2 kinds selected from Polygonum cuspidatum Sieb. et Zucc., Polygonum cuspidatum Sieb. et Zucc. Var. hachidyoense Ohwi and Polygonum sachalinense Fr. Schm. Component B: An extract of 1 kind or &gt;=2 kinds selected from plants belonging to the genus Lupinus L. Component C: An extract of Helianthus annuus L.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of expressing preventing and curing activities for diseases accompanied with bone-weight decrease, hypertension, etc., by bringing the composition to contain a stilbene compound included in polygonaceous plants, vitraceous plants, etc. SOLUTION: This medicinal and food composition containing a stilbene-based compound contains at least one species selected from compounds expressed by the formula [A and B are each a halogen, amino, amidino, anilinoamide, mercapto, sulfonic acid, etc.; (n) and (m) are each 0-5], (e.g. 4,4&#39;-stilbene diol, 3,5-stilbene diol, etc.), and its polymers as effective ingredients. The compound of the formula and its polymer are preferably originated from one or more of plants selected from a group comprising polygonaceous plants, vitaceous plants, Veratrum grandiflorum, mulberry and peanut. The composition preferably contains vitamin C, vitamin D and vitamin K. The composition is effective for preventing or curing diseases accompanied by bone weight loss, preferably osteoporosis and the like.
Autologous T cell vaccines and methods for their production are described. Also described are methods for treating T cell associated diseases such as multiple sclerosis and rheumatoid arthritis using the autologous T cell vaccines. The figure shows that the precursor frequency of circulating MBP-reactive T cells detected in MS patients at baseline (14x 10-5) was highly comparable to that reported in previous studies (approximately 10 x10-5 in peripheral blood mononuclear cells) (Zhang et al., 1994, Ota et al., 1990). No significant difference was found in the precursor frequency of MBP-reactive T cells between RR-MS and SP-MS cohorts. The T cell frequency was undetectable in 92% of patients or declined substantially in the remaining patients 2-3 months after the completion of three courses of vaccination (14x10-5 VS. 1.9x 10-5, p &lt; 0.0001). The results confirmed depletion of MBP-reactive T cells by T cell vaccination in patients with MS.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an energy modifying agent having an eliminating action an active oxygen by a new mechanism of action.  &lt;P&gt;SOLUTION: This energy modifying agent comprises a plant extract having a modifying action on the high reactivity of an active oxygen molecular seed to light energy and releasing the energy to the outside. A cosmetic composition comprises the energy modifying agent. A food or beverage comprises the energy modifying agent. Since the energy modifying agent has the modifying action on the high reactivity (high energy) of the active oxygen molecular seed to light energy and releasing the energy to the outside, the active oxygen molecular seed can safely by eliminated in the organisms. Various disorders of organisms including skin disorders caused by the active oxygen can be improved by applying the cosmetic composition or the food or beverage composition containing the energy modifying agent and prevention and improvement of skin aging can be performed thereby.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
FIELD: medicine, stomatology, pharmacy. SUBSTANCE: invention relates to production of medicinal preparations. Medicinal film for treatment of parodontium inflammatory diseases comprises medicinal agent and film base. The preparation &#34;Piyavit&#34; is used as medicinal agent. Agent comprises carboxymethylcellulose sodium or sodium alginate, or their mixture and plasticizer glycerol as the base. Components are taken in the definite quantitative content. Film provides high therapeutic effect and prolonged action of medicinal agent on mucosa tissue of mouth cavity. EFFECT: enhanced effectiveness of film and treatment.
NEW MATERIAL:A polyprenyl based compound expressed by formula I (n is 1-3; R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is H or lower alkyl) and salt thereof. EXAMPLE:7-Hydroxymethyl-3,11,15-trimethyl-2,4,6,10,14-hexadecapentaenoic acid. USE:The compound is useful as an anticancer agent, which exhibits excellent anticancer effect, has high safety and is capable of continuously using for long periods and administered orally or parenterally. PREPARATION:For example, a compound expressed by formula II is reacted with a Wittig reagent derived from formula III (X is halogen; R&lt;3&gt; is lower alkyl) to provide a compound expressed by formula IV in a compound expressed by formula I. The compound expressed by formula IV is then hydrolyzed to afford a compound expressed by formula V in the compound expressed by formula I. Above mentioned Wittig reagent is, for example, phosphorus compound obtained by reacting the compound expressed by formula III with triphenyl phosphine, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair growth- or hair restoration-promoter that is inexpensive and easy to use and achieves considerable effects.  &lt;P&gt;SOLUTION: The hair growth- or hair restoration-promoter comprises a broth without no other additives as it is obtained by extraction from leaves of Bambusa glaucescens by boiling with water. A very small amount of a perfume or the like may be added thereto. The thus-obtained promoter is put into a container that allows sprinkling or a container with a spray, for example, like a container for hair-dressing agents and is sold. The promoter is applied by directly sprinkling on scalp in the same manner as hair-dressing agents. The promoter can be used as a mixture with warm water for hair washing.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a system with which supplements can be effectively purchased.  &lt;P&gt;SOLUTION: The system comprises the terminal of analysis organization, the terminal of a patient, and the terminal of manufacturing organization, and the respective terminals are connected via the Internet. The terminal of the analysis organization transmits analysis result data of urine, a shortage of vitamins, indications of minerals, and names of supplements purchase of which is recommended to the terminal of the patient. The terminal of the patient receives the analysis result, the shortage of vitamins, the indications of minerals, and the names of the recommended supplements from the terminal of the analysis organization and displays them. The terminal of the manufacturing organization has a function to receive and display information from the terminal of the patient.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To obtain from seaweed the title composition for fish feed for preventing an abnormal phenomenon in ocean culture by mixing a highly unsaturated fatty acid obtained from the lipid part of a red alga &#39;Fudaraku&#39; with a saturated fatty acid. CONSTITUTION:The composition comprises a liquid formed from 38-55 pts.wt. highly unsaturated fatty acid obtained from the lipid part of a red alga &#39;Fudaraku&#39; and 30-50 pts.wt. fatty acid. A highly unsaturated oil or fat with advanced function, such as eicosapentaenoic acid(EPA), cannot be formed in the body of fish. Accordingly, the conventional feed for the cultivation of fish, etc., which contains no or little EPA tends to result in an abnormal growth of a fry. The composition prepared from the seaweed can prevent the abnormality when added to the feed for the cultivation of fish, etc.
An interactive educational and decision making method and system predominantly pertains to information associated with the diagnosis, treatment, and continued learning that is associated with the innumerable forms of cancer and other diseases. Preferably, a web or mobile application is employed that allows users to quickly and simply understand a variety of highly technical molecular and genetic information pertaining to these cancers, and make calculated medical decisions. Physicians can upload patient specific data to a separate HI&amp;&amp;%%PAA compliant database. Specific patient data can then be used in conjunction with the application to arrive at an effective genomic or biomarker-based treatment. The decision making process may involve at least tumor types, pertinent genes, signaling pathways, targeted drugs, and genetic and other molecular tests. These tools provide information to administer targeted methodologies to treat and diagnose cancer based on genomic data by combining elements of pharmacology, biology, and pathology and laboratory medicine.
A system and method non-invasive biomedical optical imaging and spectroscopy with low-level light is described. The technique consists of a modulated light source (120) coupled to tissue (100) of a patient to introduce excitation light. Fluorescent light emitted in response to the excitation light is detected with sensor (148). The AC intensity and phase of the excitation and detected fluorescent light is provided to a processor (160) operatively coupled to sensor (148). Processor (160) employs the measured re-emission kinetics of excitation and fluorescent light to &#34;map&#34; the spatial variation of one or more fluorescence characteristics of the tissue (100). The fluorescence characteristic may be provided by exogenous contract agents, endogenous fluorophores, or both. The variations is determined by solving frequency domain diffusion equations at a number of designated points in the tissue as part of a recursive estimation algorithm. Processor (160) generates an imaging signal in accordance with the spatial variation of the fluorescence characteristic for provision to an output device (164). The output device (164) displays an image corresponding spatial variation of the fluorescence characteristic which corresponds to tissue (100) to aid in the detection and diagnosis of disease.
PURPOSE:An anticancer agent containing an indeno[1,2-c]pyrazole derivative as an active constituent, and having a low toxicity, particularly very weak inhibitory action on myeloma unique to the anticancer agent. CONSTITUTION:An anticancer agent containing a compound expressed by the formula (R&lt;1&gt; is H or methyl; R&lt;2&gt; is phenyl or pyridyl which may or may not have a substituent group; X is carbonyl or methylene which may or may not have a substituent group) as an active constituent. The dosage form is a tablet, capsule, granule or syrup, etc. for oral administration or injection or suppository, etc. for parenteral administration. The dose thereof is 20mg-1g/day/man for oral administration and 2-300mg/day/man for parenteral administration. The compound expressed by the formula (R&lt;1&gt; is H; X is carbonyl) is synthesized by reacting the corresponding 2-acyl-1,3-indanedione with hydrazine.
In clinical documentation, mere documentation of a condition in a patient&#39;s records may not be enough. To be considered sufficiently documented, the patient&#39;s record needs to show that no documentation drop-offs (DDOs) have occurred over the course of the patient&#39;s stay. However, DDOs can be extremely difficult to detect. To solve this problem, the invention trains time-sensitive deep learning (DL) models on a per condition basis using actual and/or synthetic patient data. Utilizing an ontology, grouped concepts can be generated on the fly from real-time hospital data and used to generate time-series data that can then be analyzed by trained time-sensitive DL models to determine whether a DDO for a condition has occurred during the stay. Non-time-sensitive models can be used to detect all the conditions documented during the stay. Outcomes from the models can be compared to determine whether to notify a user that a DDO has occurred.
PURPOSE:To obtain a hair rinse agent composition having improved stability and rinse effect, containing no hydrophilic nonionic surface active agent, by preparing a highly concentrated emulsion from a small amount of a cationic surface active agent and a large amount of a specific oil, diluting it with water. CONSTITUTION:A hair rinse agent composition contaning (A) 0.05-0.5wt% cationic surface active agent such as a compound shown by the formula I (1-2 of R1-4 are 8-22C alkyl, etc., and the rest are 1-3C alkyl, etc.; X is halogen, etc.) and (B) 3-15wt% higher alcohol (e.g., alcohol having 12-26C alkyl, or alkynyl) having &gt;=45 deg.C melting point or a glycerine monofatty acid ester [e.g., one shown by the formula II (R5 is 11-23C hydrocarbon)] based on the component A. In the preparation, a highly concentrated emulsion having 0.4-36wt% total amounts of the components A and B is diluted with 1-20 times as much water as the emulsion by weight. The composition may be further blended with 0.1-5wt% water-soluble high polymer compound as the component C. It is stable independent of temperature.
PURPOSE:To obtain the subject compound useful as a synthetic intermediate for penem compounds known as agents for the treatment of microbism by reacting a penem allyl derivative with an allyl receptor in the presence of a bivalent palladium salt and its reducing agent. CONSTITUTION:The compound of formula III (R&lt;3a&gt; is H or acetoxymethyl) is produced by reacting a compound of formula I (R&lt;1&gt; is H or hydroxyl-protecting group; R&lt;2&gt; is organic group) with an allyl acceptor in the presence of a bivalent palladium salt (e.g. palladium acetate) and its reducing agent (e.g. triethyl phosphite) in a solvent (e.g. THF-methylene chloride) at -20 to +50 deg.C, optionally reacting the obtained compound of formula II or its salt with a halogenomethylacetal and optionally removing the protecting groups from the product. The allyl acceptor is e.g. 2-alkylhexanoic acid alkali metal salt.
PROBLEM TO BE SOLVED: To obtain a separating material for dental use capable of preventing the adhesion of a resin used as an adhesive, a restorative agent, etc., in the dental treatment to a contact surface of a dentin surface, a prosthesis surface, a mucous membrane surface in an oral cavity, etc., and easily separating both and good in operating efficiency such as coating or removal. SOLUTION: This separating material contains (A) 15-95 pts.wt. of a water-soluble or a water-dispersible hydroxyl group-containing compound having at least two hydroxyl groups in the molecule and &lt;=15 deg.C solidifying point, e.g. ethylene glycol and (B) 5-85 pts.wt. of a water-soluble or a water-dispersible hydroxyl group-containing compound having at least two hydroxyl groups in the molecule and &gt;=30 deg.C solidifying point, e.g. polyethylene glycol [the sum total of ingredients (A) and (B) is 100 pts.wt.].
PURPOSE:The titled high caloric composition, containing an egg white hydrolyzate obtained by reacting an acidic proteolytic enzyme with a raw material egg white solution of specific proteinic concentration, heating the reaction product at a specific temperature, and removing coagulated materials as a main component. CONSTITUTION:A raw material egg white is diluted with water, etc. to give an aqueous solution of the egg white in 1-6%, preferably 2-5%, proteinic concentration. An organic or inorganic acid is then added to the resultant aqueous solution to adjust the pH to an acidic value (3-4pH). An acidic proteolytic enzyme, e.g. a protease such as &#39;&#39;Orientase 5A &#39;&#39; produced by a microorganism of the genus Aspergillus, is then added to the aqueous solution to hydrolyze the aqueous solution at 50-60 deg.C to give the aimed aqueous solution of the egg white hydrolyzate, which is heated at 80-100 deg.C. The formed coagulated materials are removed by the centrifugation, etc. and the remaining liquid is concentrated and dried to afford a composition for supplying nutriments, containing 1-80wt% egg white hydrolyzate, and capable of recovering the physical strength rapidly with slight side effects.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a product in which a positioning feature for discriminating the positioning feature of a film-like product or a strip-like product.  &lt;P&gt;SOLUTION: The positioning feature formed to aid a user in differentiating, distinguishing or confirming one or more features of the film product or the strip product is installed to the film product or the strip product. By using the positioning feature, proper or desired use of the film product can be facilitated in discriminating the desired feature thereof. In one embodiment, the positioning feature is constituted to aid in properly orienting and/or positioning and/or applying the film product or the strip product. The film product or the strip product is able to provide a therapeutic effect to a desired treatment site, and may require positional orientation before application to the treatment site and/or positional orientation with respect to the treatment site.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
The invention disclosed a kind of complex ofloxacin injection as well as preparing method. The injection contains 5-20 shares of ofloxacin, 5-25 shares of sulphuric acid colistin, 1-20 shares of trimethoprim and 50-300 shares of propylene glycol. The preparing procedure includes the following steps: (1) weighing materials; (2) putting the sulphuric acid colistin into injection water, stirring until it&#39;s all soluble; (3) heating propylene glycol to 75-85DEG C, adding trimethoprim, stirring to make it soluble; (4) putting together the solution of step (2) and (3), clarifying the solution, regulating the ph value of the solution, adding water to 1000 shares to get the preparation. Ofloxacin has the antibacterial activity of the third generation quinolones which can inhibit the bacteria prokaryotic cell DNA gyrase and DNA replication. Sulphuric acid colistin has no residue and side effects in animal bodies. The combination of the two medicines can widen the antibacterial spectrum and increase the curative effect.